Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced an agreement with the Medicines Patent Pool (MPP) to
license its pediatric formulations of raltegravir for use in treating
HIV-1 infection in infants and children from four weeks to under 12
years of age in developing countries. This is the MPP’s first agreement
to provide access to an HIV integrase inhibitor for use in combination
HIV therapy for infants and children in this age range.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Ian McConnell, 908-740-1921orInvestors:Joe Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news